Buy VKTX by Feb 4, 2027.

I’m bullish on VKTX, both short term and long term. Short Term Outlook: Viking Therapeutics recently(January, 8th) announced the conducting a Phase 2 clinical trial, known as the VENTURE-Oral Dosing Trial, to evaluate an oral tablet formulation of VK2735 for weight management. With them also having an earnings report coming up February, 5th after market close, I believe they will give good future guidance, as well as some positive feedback on their current trials. Additionally, VKTX has increased in value …